health economics and outcomes research

A study presented at the European Lung Cancer Congress investigated the effects of multiple therapies on symptom management in ALK-positive non-small cell lung cancer.
Lucio N Gordan, MD, shared a variety of data suggesting that the general trend of cancer therapy being moved from the community setting to the hospital outpatient setting has resulted in significant cost increases.
In comparison to the funding and survival rate of many other cancer types, funding for ovarian, cervical, and uterine cancer does not align with their survival rates.
Brian Bastean, PharmD, MBA, has identified some of the most important and influential research in recent months contributing to value-based care, health economics and outcomes research, and clinical pathways.
A recent study confirmed the most cost-effective treatment option in heavily pretreated patients with relapsed or refractory multiple myeloma.
An early palliative care consultation may relieve financial burden up to 28% for patients with advanced cancer.
Duke Cancer Institute has developed a community health program focused on minimizing cancer disparities and improving overall health.
Previously-treated patients with stage IV NSCLC are less likely to utilize palliative care or hospice services compared with those who receive no prior oncologic treatment.

The International Myeloma Foundation (IMF)–the oldest and largest organization dedicated to improving the lives of myeloma patients while working toward a cure–has issued a statement calling a report by the Institute for Clinical and Economic Review (ICER) on the value of myeloma drugs overly simplistic and one that could limit patient access to optimal treatments.